GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Arix to Present at Mello Investment Trusts & Funds

6 Dec 2022 07:00

Arix Bioscience PLC (ARIX) Arix to Present at Mello Investment Trusts & Funds 06-Dec-2022 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


 

Arix Bioscience plc

 

Arix to Present at Mello Investment Trusts & Funds

 

LONDON, 6 December 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces that the Company will be presenting at the Mello Investment Trusts & Funds virtual webinar, taking place between 2pm and 5pm on Tuesday 13 December 2022.

 

Robert Lyne, CEO, will provide a live update and Q&A session on the Company, its investment strategy and outlook, at 2.30pm on the day.

 

The presentation will be hosted online and is open to all existing and potential shareholders. Individuals wishing to attend can register via the below link:

 

https://melloevents.com/mello-investment-trusts-and-funds/

 

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


ISIN:GB00BD045071
Category Code:MSCL
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:206324
EQS News ID:1505503
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
10th Mar 20177:00 amRNSHolding(s) in Company
8th Mar 20177:00 amRNSHolding(s) in Company
6th Mar 20177:00 amRNSHoldings in Company
6th Mar 20177:00 amRNSHoldings in Company
2nd Mar 20177:00 amRNSArix signs strategic agreement with Takeda
28th Feb 20174:30 pmRNSMid-Stabilisation Period Announcement
22nd Feb 20178:08 amRNSArix Bioscience - admission to trading
17th Feb 20177:01 amRNSStabilisation Notice
17th Feb 20177:00 amRNSArix Bioscience raises £100m in IPO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.